Study on amino acid metabolic spectrum and characteristic amino acid markers of children with different syndromes of bronchial asthma

注册号:

Registration number:

ITMCTR2025001058

最近更新日期:

Date of Last Refreshed on:

2025-05-28

注册时间:

Date of Registration:

2025-05-28

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

不同证候儿童支气管哮喘氨基酸代谢谱及其特征性氨基酸标志物研究

Public title:

Study on amino acid metabolic spectrum and characteristic amino acid markers of children with different syndromes of bronchial asthma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同证候儿童支气管哮喘氨基酸代谢谱及其特征性氨基酸标志物研究

Scientific title:

Study on amino acid metabolic spectrum and characteristic amino acid markers of children with different syndromes of bronchial asthma

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

万力生

研究负责人:

万力生

Applicant:

Wanlisheng

Study leader:

Wanlisheng

申请注册联系人电话:

Applicant telephone:

18938690468

研究负责人电话:

Study leader's telephone:

18938690468

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1875684406@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1875684406@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市福田区深圳市儿童医院

研究负责人通讯地址:

广东省深圳市福田区深圳市儿童医院

Applicant address:

Shenzhen Children's Hospital Futian District Shenzhen City Guangdong Province

Study leader's address:

Shenzhen Children's Hospital Futian District Shenzhen City Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市儿童医院

Applicant's institution:

Shenzhen Children's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

202501902

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

深圳市儿童医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shenzhen Childrens Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025/4/18 0:00:00

伦理委员会联系人:

李晨曦

Contact Name of the ethic committee:

Lichenxi

伦理委员会联系地址:

深圳市儿童医院伦理办公室

Contact Address of the ethic committee:

Ethics Office of Shenzhen Childrens Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

075583008379

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1393442689@qq.com

研究实施负责(组长)单位:

广东省深圳市福田区深圳市儿童医院

Primary sponsor:

Shenzhen Children's Hospital Futian District Shenzhen City Guangdong Province

研究实施负责(组长)单位地址:

广东省深圳市福田区莲花街道福新社区益田路7019号深圳市儿童医院

Primary sponsor's address:

Shenzhen Children's Hospital Futian District Shenzhen City Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

深圳市

Country:

China

Province:

Guangdong province

City:

Shenzhen city

单位(医院):

深圳市儿童医院

具体地址:

深圳市福田区深圳市儿童医院

Institution
hospital:

Shenzhen Children's Hospital

Address:

Shenzhen Children's Hospital Yitian Road Futian District Shenzhen

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation

研究疾病:

儿童支气管哮喘

研究疾病代码:

Target disease:

Bronchial asthma in children

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

病例研究

Case study

研究所处阶段:

Study phase:

其它

Others

研究目的:

通过靶向氨基酸代谢组学技术,检测不同证候哮喘患儿的血浆、尿液和呼气冷凝液样本中氨基酸谱和氨基酸含量水平及给予中药干预后氨基酸谱中氨基酸水平的变化,筛选出不同证候儿童支气管哮喘患儿的特征性氨基酸并构建模型进行验证。

Objectives of Study:

By targeting amino acid metabolic omics technology the amino acid spectrum and amino acid content levels in plasma urine and exhaled condensate samples of children with different syndromes of asthma were detected and the changes in amino acid levels in the amino acid spectrum after giving Chinese medicine intervention were detected. The characteristic amino acids of children with different syndromes of bronchial asthma were screened and a model was constructed for verification.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

符合儿童支气管哮喘西医诊断标准。符合风寒束肺证、痰热阻肺证、外寒内热证和肺实肾虚证中医证候诊断标准。年龄为 5-14 岁门诊患儿。经患儿法定监护人同意、能配合治疗及采样者,并有监护人签署知情同意书。患儿入组前未接受过其他治疗方案。 健康对照组纳入标准: 与试验组同一地区健康儿童。 与试验组无血缘关系,无哮喘及肺系疾病。 年龄为 5-14 岁儿童。 需获得患儿法定监护人知情同意,并签署知情同意

Inclusion criteria

It conforms to the Western medicine diagnostic criteria for bronchial asthma in children. It conforms to the diagnostic criteria of traditional Chinese medicine for the syndromes of wind-cold constricting the lung phlegm-heat obstructing the lung external cold and internal heat and lung solid and kidney deficiency. Children aged 5-14 years old who come to the clinic. With the consent of the child's legal guardian who can cooperate with treatment and sampling and with the guardian signing the informed consent form. The patient had not received any other treatment before entering the study. Inclusion criteria for the healthy control group: Healthy children in the same area as the experimental group. There is no blood relationship with the experimental group no asthma and pulmonary diseases. Children aged 5-14. The informed consent of the child's legal guardian must be obtained and signed.

排除标准:

不符合纳入标准的任意一项者。 心源性哮喘、先天性心血管疾病、先天性气道畸形及气管异物吸入等所致的喘息性疾病患儿。 合并心脑血管、肝肾及造血系统等其他原发性疾病及精神、神经系统疾病的患儿;或有免疫缺陷功能的患儿。 患儿法定监护人不同意配合治疗及采样者,临床资料信息不全的患儿。 对本课题研究所服用药物有过敏现象者

Exclusion criteria:

Anyone who does not meet the inclusion criteria. Children with wheezing diseases caused by cardiogenic asthma congenital cardiovascular disease congenital airway malformation and inhalation of tracheal foreign body. Children with other primary diseases such as cardiovascular and cerebrovascular liver and kidney and hematopoietic system diseases as well as mental and nervous system diseases; Or children with immunodeficiency function. Children whose legal guardians do not agree to cooperate with treatment and sampling and children whose clinical information is incomplete. Those who have allergic reactions to the drugs used in this study

研究实施时间:

Study execute time:

From 2025-01-01

To      2028-12-31

征募观察对象时间:

Recruiting time:

From 2025-06-15

To      2027-01-01

干预措施:

Interventions:

组别:

肺实肾虚证组

样本量:

30

Group:

Lung solid and kidney deficient group

Sample size:

干预措施:

苏子降气汤中药配方颗粒

干预措施代码:

Intervention:

Zi su jiang qi decoction Chinese herbal formula granules

Intervention code:

组别:

健康对照组

样本量:

30

Group:

Healthy control group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

痰热阻肺证组

样本量:

30

Group:

Phlegm-heat obstructing the lung group

Sample size:

干预措施:

麻杏石甘汤合苏葶丸中药配方颗粒

干预措施代码:

Intervention:

Ma Xing Shi Gan Decoction combined with Su Ting Pill Chinese herbal formula granules

Intervention code:

组别:

外寒内热证组

样本量:

30

Group:

Group of external cold and internal heat

Sample size:

干预措施:

大青龙汤中药配方颗粒

干预措施代码:

Intervention:

Big Qinglong Decoction Chinese herbal formula granules

Intervention code:

组别:

风寒束肺证组

样本量:

30

Group:

Wind-cold confinement to the lung group

Sample size:

干预措施:

祛风蠲饮汤中药配方颗粒

干预措施代码:

Intervention:

Medicinal formula granule for dispelling wind and eliminating phlegm

Intervention code:

样本总量 Total sample size : 150

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东省

市(区县):

深圳市

Country:

China

Province:

Guangdong province

City:

Shenzhen city

单位(医院):

深圳市儿童医院

单位级别:

三甲

Institution/hospital:

Shenzhen Children's Hospital

Level of the institution:

The top three

测量指标:

Outcomes:

指标中文名:

疗效指数

指标类型:

次要指标

Outcome:

Efficacy index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

次症评分标准

指标类型:

次要指标

Outcome:

Sub-symptom score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主症评分标准

指标类型:

主要指标

Outcome:

Main symptom scoring

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

标本中文名:

呼气冷凝液

组织:

Sample Name:

Exhaled condensate

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 5
Min age years
最大 14
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

中医诊治医生使用辨证论治方法确认证型分组,根据年龄随机排列组合产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Chinese medicine diagnosis and treatment doctors use the method of syndrome differentiation and treatment to confirm the grouping of syndromes and generate a random sequence by randomly arranging and combining the syndromes according to age.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表和电子采集与管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Medical record form and electronic collection and management system

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above